Production of Chimeric Monoclonal Antibodies Against Burkholderia Bacteria
Author Information
Author(s): Kim Hyung-Yong, Tsai Shien, Lo Shyh-Ching, Wear Douglas J., Izadjoo Mina J.
Primary Institution: Department of Environmental and Infectious Disease Sciences, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, D. C., United States of America
Hypothesis
The study aims to develop chimeric mouse-human monoclonal antibodies (cMAbs) against Burkholderia pseudomallei and Burkholderia mallei using a specific expression system.
Conclusion
The developed cMAbs showed potential for therapeutic use against infections caused by Burkholderia species.
Supporting Evidence
- The study generated and characterized over 100 mouse monoclonal antibodies against Burkholderia species.
- Three specific cMAbs were developed and shown to react with different bacterial antigens.
- The cMAbs were produced using a dihydrofolate reductase (DHFR) amplification system in CHO cells.
Takeaway
Scientists created special antibodies that can help fight off infections from certain harmful bacteria found in soil and water.
Methodology
The study involved constructing different vector systems for stable production of cMAbs in mammalian cells and optimizing transfection conditions.
Limitations
The study may have limitations in the generalizability of the findings to all strains of Burkholderia due to the close homology among species.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website